CGD Association

The Fungal Research Trust is a UK-based not-for-profit charity, which was formed in 1991. They have set up a major Internet website at http://www.aspergillus.man.ac.uk on one fungus and the diseases it causes - namely Aspergillus and aspergillosis. This should provide a major resource for clinical doctors and scientists faced with patients with this problem and/or laboratory problems.

Although much of the material is geared toward doctors and scientists, two sections of interest for the layman are: “Just What is Aspergillus?” This question and answer has been translated into twenty-seven languages and more languages will be added. The second section is “The Aspergillus diseases e-mail discussion group.” This e- mail discussion group was set up in February 1999 as a forum for patients and their relatives to share their concerns and experiences of Aspergillus diseases.

Aspergillosis in CGD is discussed. In regards to prophylaxis against Aspergillus infections, Dr. D.W. Denning (Department of Infectious Diseases and Tropical Medicine, Monsall Unit, North Manchester General Hospital, Manchester, UK) stated, April 1998, that .Units that have adopted itraconazole prophylaxis have seen a fall in the incidence of Aspergillus infections, although not to zero. This implies that patients may be non-compliant, especially during adolescence, that absorption may be inadequate, the dose used was too low for the patients weight or that the patients with infection were infected with itraconazole-resistant isolates.

Various therapies for invasive pulmonary aspergillosis are mentioned: combination therapy with amphotericin B; amphotericin in intralipid; amphotericin B; lipid-associated and liposomal amphotericin B; and itraconazole.

Four new drugs for aspergillosis are described: liposomal nystatin (Nyotran); voriconazole; terbinafine (Lamisil), and MK-0991. Of particular interest is voriconazole, introduced in 1995. It is a promising new triazole antifungal with a broad spectrum of activity including Aspergillus. There are ongoing clinical studies in the use of voriconazole in the treatment of acute aspergillosis in immunocompromised patients in Europe, Israel, Middle East, Australia, Canada, Central and South America, India, and the USA.

There are separate discussion groups that allow doctors, scientists, and patients to post their current concerns, such as: fungal resistance, Aspergillus exposure and prevention. This website is highly recommended for all those concerned with Aspergillus.

Dr. Fungus (please see website for current updates)

This is another excellent website with references to all things mycological! It is the official website of the Mycoses Study Group.


	Welcome Do I Have CGD? After Being Diagnosed General Information about CGD Doctor Visits & Hospitalizations Specific Infecting Organisms Drug Therapies Your Time in the Hospital Support for the Patient Services for the Patient Sibling Support Bereavement Fundraising Donation Suggestions Links Contact & Nonprofit Info		Specific Infecting Organisms Superb Aspergillus Website (please see website for current updates) The Fungal Research Trust is a UK-based not-for-profit charity, which was formed in 1991. They have set up a major Internet website at http://www.aspergillus.man.ac.uk on one fungus and the diseases it causes - namely Aspergillus and aspergillosis. This should provide a major resource for clinical doctors and scientists faced with patients with this problem and/or laboratory problems. Although much of the material is geared toward doctors and scientists, two sections of interest for the layman are: “Just What is Aspergillus?” This question and answer has been translated into twenty-seven languages and more languages will be added. The second section is “The Aspergillus diseases e-mail discussion group.” This e- mail discussion group was set up in February 1999 as a forum for patients and their relatives to share their concerns and experiences of Aspergillus diseases. Aspergillosis in CGD is discussed. In regards to prophylaxis against Aspergillus infections, Dr. D.W. Denning (Department of Infectious Diseases and Tropical Medicine, Monsall Unit, North Manchester General Hospital, Manchester, UK) stated, April 1998, that .Units that have adopted itraconazole prophylaxis have seen a fall in the incidence of Aspergillus infections, although not to zero. This implies that patients may be non-compliant, especially during adolescence, that absorption may be inadequate, the dose used was too low for the patients weight or that the patients with infection were infected with itraconazole-resistant isolates. Various therapies for invasive pulmonary aspergillosis are mentioned: combination therapy with amphotericin B; amphotericin in intralipid; amphotericin B; lipid-associated and liposomal amphotericin B; and itraconazole. Four new drugs for aspergillosis are described: liposomal nystatin (Nyotran); voriconazole; terbinafine (Lamisil), and MK-0991. Of particular interest is voriconazole, introduced in 1995. It is a promising new triazole antifungal with a broad spectrum of activity including Aspergillus. There are ongoing clinical studies in the use of voriconazole in the treatment of acute aspergillosis in immunocompromised patients in Europe, Israel, Middle East, Australia, Canada, Central and South America, India, and the USA. There are separate discussion groups that allow doctors, scientists, and patients to post their current concerns, such as: fungal resistance, Aspergillus exposure and prevention. This website is highly recommended for all those concerned with Aspergillus. Dr. Fungus (please see website for current updates) This is another excellent website with references to all things mycological! It is the official website of the Mycoses Study Group.